Fact-checked by Grok 2 weeks ago

Lichen simplex chronicus

Lichen simplex chronicus (LSC), also known as neurodermatitis, is a common chronic skin disorder characterized by thickened, scaly, and intensely y patches of skin that develop as a result of repeated or rubbing in response to persistent pruritus. This condition arises from a vicious cycle where initial ing leads to mechanical trauma, causing lichenification—a leathery thickening of the —and further exacerbating the . LSC is not contagious or life-threatening but can significantly impair due to sleep disruption and emotional distress. The etiology of LSC typically involves an initial trigger that initiates the itch-scratch cycle, such as skin conditions like , , or dry skin (xerosis), as well as external irritants including insect bites, tight clothing, or chemical exposures. Psychological factors, including , anxiety, and , play a significant role in perpetuating the condition, often worsening symptoms during periods of emotional tension. Risk factors include a history of other dermatoses, family predisposition to allergies or eczema, and being in the 30-50 age group, with a higher prevalence among females at a ratio of approximately 2:1. It affects self-accessible body areas, most commonly the , wrists, ankles, forearms, and anogenital region, though it can occur on the or elsewhere. Clinically, LSC presents with well-defined, hyperpigmented plaques that are rough, dry, and excoriated, with itching that intensifies at night or during inactivity. Over time, may develop open sores, fissures, or secondary bacterial if persists. is primarily based on clinical , with a occasionally used to rule out mimics like or lichen amyloidosis. Management focuses on interrupting the itch-scratch cycle through topical corticosteroids to reduce , emollients to hydrate the skin, and occlusive dressings to prevent access to affected areas. Antihistamines, anxiolytics, or behavioral therapies such as address pruritus and psychological contributors, while stress reduction techniques like counseling are recommended for long-term control. The is generally favorable with adherence to , though relapses are common, and complications such as scarring, permanent pigmentation changes, or chronic infections may occur in severe cases.

Overview and Epidemiology

Definition

Lichen simplex chronicus is a chronic dermatosis characterized by the development of thickened, scaly patches resulting from repeated trauma, such as habitual or rubbing, which induces an itch-. This condition manifests as lichenification, a process involving epidermal , , and accentuation of markings due to prolonged . Classified as a form of neurodermatitis within the broader spectrum of pruritic dermatoses, lichen simplex chronicus is typically viewed as a secondary reactive process rather than a primary dermatological disease, often arising in response to underlying pruritus from various etiologies. The term originates from early dermatological descriptions, associated with Émile Vidal and Josef Jadassohn, highlighting its circumscribed lichen-like changes. Key morphological features include well-demarcated plaques of leathery, thickened skin with exaggerated skin markings, commonly affecting extensor surfaces such as the neck and ankles.

Epidemiology

Lichen simplex chronicus is a prevalent dermatological , with estimates indicating it affects approximately 12% of the general and represents one of the most common causes of in clinical settings. In clinics, it accounts for 2.5-5% of adult presentations in populations, rising to 10-35% among women attending specialized vulvar clinics. These figures underscore its significance in pruritic populations, where it often complicates underlying skin s. Demographically, the condition predominantly affects adults, with peak incidence between 30 and 50 years of age. It exhibits a female predominance, with a 2:1 female-to-male , and is more frequent in individuals with atopic backgrounds, such as those with a history of . Racial disparities show higher rates among Black and Asian patients compared to White populations. Geographically, lichen simplex chronicus demonstrates variations, with elevated reported in tropical regions, potentially due to increased to irritants and . It is rare in pediatric populations but can occur in children, particularly those with .

Clinical Presentation

Signs and Symptoms

Lichen simplex chronicus is characterized by intense pruritus as the primary symptom, often described as severe and persistent itching that intensifies at night or during periods of relaxation, perpetuating a vicious itch-scratch cycle through repetitive scratching and rubbing. Visible signs include well-demarcated lichenified plaques, which appear as thickened, leathery patches of with exaggerated skin markings, (often reddish-brown or violaceous, more prominent in individuals with darker tones), and dry ; these may be accompanied by excoriations from and, in some cases, secondary bacterial infections presenting as crusting or oozing. The condition commonly affects accessible body areas, such as the anogenital region, of the neck (known as lichen Vidal), ankles, and wrists, with less frequent involvement of the palms or soles. Lesions typically begin as erythematous, itchy patches that evolve over weeks to months into chronic, indurated, hypertrophic plaques due to ongoing mechanical irritation. Patients often report to touch () in affected areas, which exacerbates the , and in severe cases, fissuring or cracking of the thickened may occur, leading to or discomfort.

Risk Factors and Associated Conditions

Lichen simplex chronicus (LSC) is influenced by a combination of modifiable and non-modifiable factors that predispose individuals to the development of chronic pruritus and subsequent changes. Modifiable factors include exposure to chronic irritants such as tight clothing, harsh soaps, and chemical allergens like p-phenylenediamine in dyes, which can initiate or exacerbate the -scratch cycle. Habitual scratching behaviors, often triggered by initial pruritic events like bites or minor , further perpetuate the condition by reinforcing localized thickening. Poor practices in easily accessible body areas, such as the or ankles, can contribute to secondary or that worsen symptoms, particularly in individuals with underlying dry (xerosis). Non-modifiable risk factors encompass genetic predispositions and demographic characteristics. A family history of atopic conditions, including eczema, hay fever, or , increases susceptibility due to inherent skin barrier vulnerabilities. The condition disproportionately affects females, with a reported 2:1 female-to-male ratio, and is most common in middle-aged adults aged 30 to 50 years. LSC frequently coexists with other dermatological and systemic conditions, highlighting its role as a secondary response to underlying pruritic disorders. LSC frequently coexists with , where impaired skin barrier function serves as a predisposing element. Comorbidities also include , , and asteatotic eczema, often arising from shared irritant exposures or venous insufficiency in lower extremities. Systemic associations involve conditions like diabetes mellitus and cholestatic liver diseases that induce generalized pruritus, occasionally leading to localized LSC. Psychological factors play a significant amplifying role in LSC, with strong links to , anxiety, and that can initiate or intensify as a mechanism. Approximately 62% of patients carry a psychiatric , including (32%) and (12%), with anxiety conferring a 41-fold increased . Obsessive-compulsive tendencies further contribute, as evidenced by studies on the emphasizing emotional distress in the 2010s. These psychodermatological connections underscore the need for integrated management addressing both dermatological and aspects.

Pathophysiology

Causes

Lichen simplex chronicus typically arises as a secondary condition triggered by persistent pruritus from underlying cutaneous disorders, such as , , or dry skin, which leads to habitual scratching and rubbing. Insect bites or scars from trauma, including , can also initiate the itch-scratch cycle in susceptible individuals. Neurological dysregulation plays a key role in the itch pathways of lichen simplex chronicus, involving non-histaminergic mediators that contribute to neurogenic inflammation. In rare instances, central or peripheral nerve damage from conditions like stroke, shingles, or back injuries can precipitate localized pruritus, prompting the chronic scratching response. Environmental factors, including exposure to allergens, heat, or mechanical friction in accessible body sites like the neck or ankles, often exacerbate or trigger the condition in predisposed areas. Associations with atopic conditions, such as eczema, are common, though the primary focus remains on the initiating rather than chronic predispositions. In many cases, particularly primary lichen simplex chronicus, no clear underlying trigger is identified, highlighting its idiopathic nature and emphasizing the role of the self-perpetuating -scratch cycle as the core mechanism.

Mechanisms of Skin Changes

The itch-scratch cycle in lichen simplex chronicus (LSC) begins with initial pruritus that activates cutaneous C-fibers, prompting repetitive scratching and mechanical to . This induces epidermal damage and release of pro-inflammatory cytokines, promoting epidermal through proliferation and inhibition of . Recent studies highlight the involvement of IL-31 and transient receptor potential (TRP) channels like and in itch signaling, alongside reduced intraepidermal density and variable levels. The cycle perpetuates as scratching further exacerbates pruritus through sensitization, creating a self-reinforcing loop of and . Chronic from sustained drives the lichenification , characterized by acanthosis (epidermal thickening) due to increased mitotic activity in the basal layer and elongation of rete ridges. This leads to , where excessive production results in a scaly, thickened , providing a protective barrier but also contributing to induration. In the dermis, chronic leads to and remodeling into denser bundles. The inflammatory cascade amplifies these changes through degranulation, releasing proteases and other mediators that heighten pruritus and recruit immune cells. T-cell infiltration, particularly Th2 cells, further sustains by secreting additional cytokines, leading to perivascular and interstitial infiltrates of lymphocytes, histiocytes, and . This chronic immune activation contributes to dermal induration via ongoing remodeling and . Neurogenic plays a key role in cycle perpetuation, with potential involvement of neuropeptides such as from sensory nerve endings. These neuropeptides enhance vascular permeability and interact with mast cells and , intensifying pruritus and ; histologically, this correlates with elongated rete ridges and thickened collagen in the papillary .

Diagnosis

Clinical Evaluation

The clinical evaluation of lichen simplex chronicus commences with a detailed history-taking to elucidate the temporal aspects and behavioral patterns of the condition. Clinicians inquire about the duration of symptoms, which typically span months to years, reflecting the chronic nature of the disorder. Itch intensity is quantitatively assessed using tools like the Visual Analog Scale (VAS), where patients mark their perceived itch severity on a 0-10 continuum, aiding in objective documentation and monitoring. Scratching habits are explored, including the frequency, triggers (such as or ), and unconscious patterns, while relief factors—like , moisturization, or environmental changes—are identified to inform subsequent steps. Physical examination forms the cornerstone of assessment, beginning with meticulous inspection of under adequate lighting to identify lichenified plaques—discrete, thickened areas with accentuated skin lines and a leathery , often exhibiting or . follows to evaluate induration, revealing firm, rubbery consistency in the lesions due to dermal . The distribution pattern is systematically documented, commonly affecting accessible body regions such as the of the , extensor forearms, ankles, and anogenital areas, which correspond to sites amenable to repeated mechanical trauma from . This topographic mapping helps confirm the self-induced . Diagnosis relies on clinical criteria, centered on the diagnostic of intractable , well-demarcated lichenification, and identifiable sites or excoriations, without the need for a single confirmatory test. Nocturnal of is often elicited in the , underscoring the cyclical reinforcement of symptoms. Adjunctive tools like dermoscopy may enhance visualization of surface changes but are not essential. Integral to the evaluation is regarding the itch-scratch cycle, wherein initial pruritus prompts scratching that thickens the and perpetuates further itching; early awareness of this feedback loop facilitates patient engagement and sets the foundation for effective intervention.

Histopathological Findings

Histopathological of biopsies from lesions of lichen simplex chronicus reveals characteristic changes reflecting chronic mechanical irritation from scratching or rubbing. The epidermis typically shows marked , often orthokeratotic, with foci of parakeratosis particularly in more active or inflamed areas. Acanthosis is prominent, accompanied by elongation and irregular thickening of the rete ridges, leading to pseudoepitheliomatous in severe cases. A thickened granular layer (hypergranulosis) is consistently observed, and mild may be present without significant . In the dermis, vertical orientation of collagen fibers is noted, along with mild , especially in the papillary dermis. A perivascular lymphocytic infiltrate is common in the superficial , sometimes with interstitial involvement and occasional eosinophils or histiocytes, but without dense inflammation or formation. The absence of viral inclusions or other specific features helps confirm the in the context of clinical lichenification. Routine special stains are not typically required, as hematoxylin and eosin suffices to highlight these features; however, may reveal fibers attached to the in advanced lesions. is generally reserved for atypical presentations, such as suspected or when clinical findings are equivocal, to support the diagnosis by excluding other dermatoses. These histologic patterns correlate well with the chronic, lichenified plaques observed clinically.

Differential Diagnosis

Lichen simplex chronicus (LSC) must be differentiated from other pruritic dermatoses that present with thickened or lichenified skin, as clinical overlap can lead to misdiagnosis. Key differentials include , which typically manifests as diffuse, erythematous patches rather than the localized, well-defined plaques of LSC. is distinguished by the presence of silvery scales and often involves extensor surfaces, features absent in LSC. Contact dermatitis requires consideration, particularly when there is a history of or irritant exposure leading to acute onset, unlike the chronic, habitual scratching pattern in LSC. Other pruritic disorders include , characterized by violaceous, polygonal papules with Wickham striae, contrasting with LSC's hyperkeratotic plaques. presents with discrete, excoriated nodules rather than the plaque-like morphology of LSC, though both share hyperkeratosis on . Neoplastic mimics such as (e.g., ) or necessitate exclusion, especially with irregular borders or ulceration; is essential for these, revealing atypical lymphocytes or malignant absent in LSC. Histological features, including epidermal without significant , can aid in distinguishing LSC from these alternatives. The diagnostic approach relies on a thorough history to identify scratching triggers, physical examination for lesion morphology, and targeted tests such as patch testing to rule out contact dermatitis or biopsy to exclude malignancy.

Management

Non-Pharmacological Approaches

Non-pharmacological approaches to managing lichen simplex chronicus primarily target the itch-scratch cycle by addressing behavioral patterns, skin barrier function, and environmental triggers, serving as first-line strategies to reduce and promote skin healing. These interventions emphasize patient empowerment through education and practical techniques, often integrated in a multidisciplinary framework involving dermatologists and psychologists. Habit reversal training (HRT) is a key behavioral intervention designed to increase awareness of scratching urges and replace them with alternative responses, thereby interrupting the cycle. The process typically involves three components: awareness training to identify triggers such as or , competing response training (e.g., clenching fists or holding an object for one minute when the urge arises), and from family or peers to reinforce adherence. Techniques like mindfulness meditation and methods, such as engaging in hobbies during high-risk times, are incorporated to enhance self-regulation. HRT has shown promise in psychodermatological conditions, with small studies indicating reductions in repetitive scratching behaviors. Skin care practices focus on restoring the barrier and minimizing irritation to alleviate pruritus without exacerbating lichenification. Regular application of emollients, particularly those containing ceramides, helps replenish and improve , reducing dryness that perpetuates itching. Patients are advised to avoid irritants such as harsh soaps, synthetic fabrics, and excessive (limiting to once daily with lukewarm ), opting instead for soap substitutes and gentle patting dry followed by immediate moisturization. Protective measures include with dressings, medicated tapes, or wet wraps—where emollient is applied to damp , covered by a moist layer of or , then a dry outer layer—to enhance , soothe , and physically prevent , especially during sleep. These practices have been shown to improve integrity and reduce severity in pruritic dermatoses. Lifestyle modifications complement behavioral and strategies by targeting modifiable risk factors that intensify the itch-scratch cycle. (CBT) is particularly effective for stress reduction, helping patients reframe anxiety-related thoughts and practice relaxation techniques like to lower overall tension that triggers scratching. Simple daily habits, such as keeping trimmed short and filed smooth to minimize trauma during inadvertent rubbing, are routinely recommended. Environmental controls, including wearing loose or clothing, using cool compresses or soaks for acute flares, and opting for breathable to mitigate nocturnal itching exacerbated by heat and sweat, further support symptom control. CBT-integrated approaches have been associated with significant improvements in and pruritus severity scores in patients with lichen simplex chronicus. Patient education is integral to all non-pharmacological strategies, emphasizing and disruption of the itch-scratch through consistent reinforcement of techniques like and routines. Educational sessions, often delivered by dermatologists in collaboration with psychologists, cover trigger identification, the importance of adherence, and when to seek multidisciplinary support for persistent cases. This approach fosters long-term self-management, with informed patients reporting better and reduced recurrence rates.

Pharmacological Treatments

The primary pharmacological approach to managing lichen simplex chronicus involves topical therapies aimed at reducing and interrupting the itch-scratch cycle. High-potency topical corticosteroids, such as 0.05% ointment, are considered first-line treatments and are typically applied once or twice daily for 2-4 weeks to thickened s, followed by a transition to lower-potency agents or intermittent maintenance dosing to sustain remission. These agents demonstrate robust efficacy, with seven randomized controlled trials supporting their use in achieving significant symptom reduction and improvement in 70-90% of cases across various studies. For sensitive areas like the genitals or face, where risk is higher, topical inhibitors such as 0.1% ointment offer an alternative, providing long-term relief without steroid-related side effects and showing improvement in pruritus and thickening in clinical observations. Systemic medications are reserved for widespread involvement, refractory cases, or when pruritus significantly disrupts sleep or daily function. Sedating antihistamines, such as hydroxyzine 25-50 mg at bedtime, effectively target nocturnal itching by promoting drowsiness and modulating responses, with limited but supportive from case series and reviews indicating reduced scratching frequency. Gabapentinoids like (starting at 75 mg daily, titrated to 150-300 mg) address the neuropathic component of chronic pruritus, demonstrating favorable responses in small cohorts of patients with lichen simplex chronicus, including resolution of lesions after 4-8 weeks of therapy. Oral corticosteroids, such as 0.5-1 mg/kg for short courses of 1-2 weeks during acute flares, may be used cautiously to rapidly severe , though is anecdotal and primarily drawn from broader pruritic dermatoses . For extensive disease, particularly with an atopic background, biologic agents such as have shown benefit in case reports and small studies. Adjunctive agents target underlying psychogenic or central factors contributing to persistent scratching. Tricyclic antidepressants like , administered orally at low doses (10-25 mg nightly) or topically as 5% cream applied up to four times daily, provide benefits through blockade and , with randomized trials showing significant reduction in patients with chronic pruritic conditions. Emerging therapies, such as inhibitors (e.g., 100-200 mg daily), have shown promise in 2020s case reports for refractory pruritic dermatoses akin to lichen simplex chronicus, though high-quality trials specific to this condition remain limited. Dosing regimens emphasize gradual tapering for corticosteroids to minimize risks like , with high-potency topicals limited to 2-4 weeks followed by twice-weekly applications for maintenance, monitored via clinical reassessment every 4-6 weeks. Systemic agents require similar vigilance, including renal function checks for gabapentinoids and electrocardiogram monitoring for to avoid cardiac effects. Overall, controlled studies report 70-80% rates for combined pharmacological approaches in achieving partial to complete remission, underscoring the need for individualized therapy to break the cycle.

Advanced Interventions

For refractory or severe cases of lichen simplex chronicus (LSC) where first-line topical and behavioral therapies fail, advanced interventions such as intralesional injections, phototherapy, and procedural options offer targeted relief by addressing persistent , lichenification, and cycles. These approaches are typically reserved for localized hypertrophic plaques or widespread involvement, aiming to break the itch-scratch cycle through direct modulation or . Selection depends on lesion characteristics, patient tolerance, and potential for recurrence, with multidisciplinary input from dermatologists often recommended. Intralesional injections of corticosteroids, such as , provide localized control for thick, unresponsive plaques by delivering anti-inflammatory agents directly into the . The procedure involves injecting 0.1-0.5 mL of triamcinolone (typically 10-40 mg/mL) at 1-2 cm intervals across the lesion, often using a pneumatic device to minimize pain and improve drug distribution. This method is particularly useful for nodular or hypertrophic LSC, yielding significant flattening and pruritus reduction in refractory cases unresponsive to topical steroids after one month. Phototherapy with narrowband ultraviolet B (NB-UVB) modulates chronic inflammation and hyperproliferation in widespread or extensive LSC, administered as 3-5 sessions per week with incremental dosing starting at 50-70% of the minimal dose. In a analysis of 26 patients (primarily children) with LSC, targeted NB-UVB achieved marked improvement or clearance in the majority, with sustained itch relief and minimal side effects like transient . This modality is effective for diffuse involvement, offering a non-invasive alternative when topical agents are insufficient. Surgical and ablative options are considered for localized hypertrophic or scarred lesions resistant to medical management. Excision may be performed for discrete, well-defined plaques to remove thickened tissue, though it carries risks of scarring and is rarely first-choice. using applied in 10-20 second freeze-thaw cycles flattens plaques and alleviates pruritus, with a 2022 of 12 randomized controlled s (n=1,066) demonstrating superior efficacy (risk ratio 1.39) when combined with topical treatments compared to topicals alone, without increased adverse events. For scarring or resistant areas, CO2 , particularly fractional CO2, resurfaces skin and improves lichenification; a randomized of 60 patients showed 93.3% achieving clear or almost clear status with plus versus 50% with alone. Emerging therapies like type A injections target neurogenic components, particularly in cases exacerbated by or autonomic dysfunction. Injections of 25-50 units into affected areas inhibit acetylcholine release, reducing the urge to scratch; a 2020 clinical trial of 12 patients with recalcitrant LSC reported significant decreases in visual analog scale scores and Eczema Area and Severity Index, with effects lasting 3-6 months and no major adverse events. Small 2020s trials support its role as an adjunct for localized, -associated pruritus unresponsive to standard care.

Prognosis and Complications

Long-Term Outcomes

Lichen simplex chronicus typically follows a chronic relapsing course, with many patients experiencing recurrent episodes triggered by , environmental factors, or persistent scratching despite initial success. Remission is achievable by interrupting the itch-scratch cycle through , though longstanding lesions often leave residual scarring or pigmentary changes. In studies of vulvar lichen simplex chronicus, combined interventions including high-intensity alongside topical agents have shown cure rates of 60-65%, with recurrence rates of 22-35% if underlying triggers like remain unaddressed. For anogenital sites, procedural therapies such as CO2 laser have yielded short-term response rates of up to 87.5% at six months, supporting better long-term control when integrated with maintenance topical corticosteroids. Prognostic outcomes improve with early intervention and absence of , as longer duration and older age correlate with reduced efficacy, while exacerbates relapse risk. Anogenital involvement portends poorer resolution due to challenges in avoiding and maintaining , often leading to more persistent compared to extragenital sites. adherence, including habit reversal techniques, further enhances sustained remission by mitigating habitual scratching. Regular follow-up is recommended to monitor for flares and adjust .

Potential Complications

Untreated or poorly managed lichen simplex chronicus (LSC) can lead to several skin-related complications due to persistent and mechanical trauma to the affected areas. Secondary bacterial frequently occur in excoriated lesions, potentially resulting in or more widespread if not addressed. Deep scratching may cause ulceration, particularly in vulnerable sites like the lower extremities, leading to delayed and increased risk. Chronic irritation often results in permanent changes, including or , as well as , which manifest as thickened, leathery plaques with reduced elasticity. Beyond localized effects, LSC can contribute to systemic issues through its impact on daily functioning and . Fibrotic changes in may exacerbate the -scratch cycle. Intense nocturnal pruritus commonly disrupts , leading to or fragmented rest patterns that impair overall . The condition is also associated with heightened anxiety and , as the unrelenting amplifies emotional stress and may worsen pre-existing psychiatric comorbidities. In longstanding plaques, particularly those with , there is a documented risk of progression to , though this remains exceptional and typically arises after years of untreated irritation. Early intervention, including breaking the itch-scratch cycle through behavioral and medical strategies, significantly mitigates these risks and prevents progression to chronic sequelae, as emphasized in dermatological guidelines. As of 2025, emerging procedural therapies like and CO2 show promise for refractory anogenital cases.

References

  1. [1]
    Lichen simplex chronicus: MedlinePlus Medical Encyclopedia
    ### Summary of Lichen Simplex Chronicus (LSC)
  2. [2]
    Lichen Simplex Chronicus - Medscape Reference
    Sep 6, 2024 · Lichen simplex chronicus (LSC) is thickening of the skin with variable scaling that arises secondary to repetitive scratching or rubbing.Practice Essentials · Pathophysiology · Etiology · Epidemiology
  3. [3]
    Neurodermatitis - Symptoms and causes - Mayo Clinic
    also known as lichen simplex chronicus — is not life-threatening or contagious. But the itching can be so intense it disrupts ...Overview · Symptoms · Risk Factors
  4. [4]
    Lichen Simplex Chronicus - StatPearls - NCBI Bookshelf
    Lichen simplex chronicus is defined as a common form of chronic neurodermatitis that presents as dry, patchy areas of skin that are scaly and thick.Continuing Education Activity · History and Physical · Treatment / Management
  5. [5]
    Scabies-induced lichen simplex chronicus misdiagnosed as ... - NIH
    Feb 17, 2021 · Lichen simplex chronicus has been defined as a localized skin condition characterized by thickening, hyperpigmentation and accentuated skin markings.
  6. [6]
    Lichen Simplex Chronicus: Clinical Perspectives and Emerging ...
    Aug 25, 2025 · Lichen simplex chronicus (LSC), also known as neurodermatitis, is a common chronic pruritic dermatosis defined by lichenified plaques ...Missing: symptoms causes
  7. [7]
    Lichen Simplex Chronicus Itch: An Update - PMC - PubMed Central
    Lichen simplex chronicus is a form of chronic localized pruritus with a secondary dermatitis, and one of the most common types of chronic itch conditions.Definition, Epidemiology... · Pathophysiology · TherapeuticsMissing: symptoms | Show results with:symptoms
  8. [8]
    Lichen simplex chronicus of Vidal - PubMed
    Lichen simplex chronicus of Vidal. Proc R Soc Med. 1910;3(Dermatol Sect):41. Author. H G Adamson. PMID: 19974231; PMCID: PMC1960908. No abstract available.Missing: history | Show results with:history
  9. [9]
    XCII. HISTOLOGY OF NEURODERMATITIS | JAMA Dermatology
    ... lichen circumscriptus des anciens auteurs ou lichen simplex chronique de M. le Dr. E. Vidal , Ann. de dermat. et syph. 2:193, 1891. 7. Becker, S. W. ...
  10. [10]
    View of Lichen Simplex Chronicus Itch: An Update | Acta Dermato ...
    Oct 17, 2022 · Lichen simplex chronicus is a form of chronic localized pruritus with a secondary dermatitis, and one of the most common types of chronic itch conditions.Missing: naming Vidal Jadassohn
  11. [11]
    Lichen Simplex Chronicus - DynaMed
    Jan 22, 2025 · Incidence/Prevalence · up to 5% of Western European and American adults · 10%-35% of women attending vulvar clinics · 2.5% of patients presenting ...
  12. [12]
    Lichen simplex chronicus (Neurodermatitis) - DermNet
    Oct 19, 2022 · Lichen simplex is a chronic itchy skin disorder characterised by well demarcated, erythematous patches, and plaques of thickened leathery skin.Images · Scrotum · Vulval lichen simplex images · Mycosis fungoidesMissing: naming history Jadassohn
  13. [13]
    Lichen Simplex Chronicus: Clinical Perspectives and Emerging ...
    Aug 25, 2025 · Despite its high prevalence—affecting up to 12% of the general population—it remains underrepresented in dermatologic literature and ...2 Epidemiology And Clinical... · 3 Pathophysiology · 5 Treatment<|control11|><|separator|>
  14. [14]
    Lichen simplex chronicus - Pathology Outlines
    Jun 12, 2025 · Lichen simplex chronicus involves localized skin changes associated with chronic rubbing and scratching.Missing: naming Vidal Jadassohn
  15. [15]
    Neurodermatitis: Symptoms, Causes, Treatments, Tests & Recovery
    Oct 10, 2019 · Neurodermatitis, also called lichen simplex chronicus, is an itchy skin condition that is most active when you are relaxing.
  16. [16]
    Lichen Simplex Chronicus - Dermatologic Disorders - Merck Manuals
    Symptoms and Signs of Lichen Simplex Chronicus. Lichen simplex chronicus is characterized by pruritic, dry, scaling, hyperpigmented, lichenified plaques ...
  17. [17]
    Lichen Simplex: What Is It, Causes, Treatment, and More - Osmosis
    Over time, the chronic scratching and rubbing leads to dry, thickened, scaly skin lesions that may appear darker than surrounding skin and inflamed.
  18. [18]
    Lichen simplex chronicus - Symptoms, diagnosis and treatment
    Risk factors · atopic diathesis · environmental irritants · psychiatric disorder · dermatologic disease · systemic conditions causing pruritus.
  19. [19]
  20. [20]
    Lichen Simplex: Causes and Treatment | Doctor - Patient.info
    Nerve dysfunction, such as due to a back injury, shingles or stroke. Lichen simplex is more common in people who feel anxious or stressed. Sometimes, no ...
  21. [21]
    Lichen simplex - British Association of Dermatologists
    Damage to the nerves, e.g. due to back injury, herpes zoster infection (shingles) or stroke can lead to lichen simplex. Sometimes, no cause can be identified.Missing: neurological | Show results with:neurological
  22. [22]
  23. [23]
  24. [24]
    Lichen Simplex Chronicus - PubMed
    Aug 7, 2023 · Lichen simplex chronicus is defined as a common form of chronic neurodermatitis that presents as dry, patchy areas of skin that are scaly and thick.
  25. [25]
    Lichen Simplex Chronicus Itch: An Update
    Oct 19, 2022 · Lichen simplex chronicus is a form of chronic localized pruritus with a secondary dermatitis, and one of the most common types of chronic itch conditions.
  26. [26]
    [PDF] Lichen Simplex Chronicus: Easy Psychological Interventions that ...
    Nov 10, 2016 · Habit reversal training has three steps: sensitization and awareness, competing response training and social support [15,23]. • Sensitization ...
  27. [27]
    Habit reversal therapy in the management of body focused repetitive ...
    ... therapy in ... effectiveness and approach of habit reversal therapy. Keywords: BFRB; Habit reversal therapy; psychocutaneous disorders; psychodermatology.
  28. [28]
    Lichen simplex - British Association of Dermatologists
    Lichen simplex describes a response to the skin being repeatedly scratched or rubbed over a long period of time (also called lichen simplex chronicus).<|control11|><|separator|>
  29. [29]
    The Role of Wet Wrap Therapy in Skin Disorders – A Literature Review
    Jun 1, 2015 · One hypothesis suggests that wet wrap therapy may trigger increased lamellar body secretion resulting in recovery of the damaged intercellular ...
  30. [30]
    Cognitive behavior therapy as dermatological treatment - NIH
    Dec 23, 2022 · Patients who underwent CBT or Internet CBT in addition to skin care demonstrated improvement with quality of life and severity of skin disease.
  31. [31]
    [PDF] Lichen Simplex Chronicus - VULVOVAGINAL DISORDERS
    Chronic itching and/or burning of the vulva. •. Waking up at night scratching. •. Skin that is pink to dusky red or purple color. •.
  32. [32]
    Lichen simplex (lichen simplex chronicus)
    Jan 31, 2025 · Lichen simplex is intensely itchy; the itch may be worse at night · There may be single or multiple areas of skin affected · Lichen simplex ...
  33. [33]
    A Simple and Effective Therapeutic Approach to Lichen Simplex ...
    Jul 13, 2020 · Moreover, application of topical corticosteroids on 'as and when required basis' improves patient compliance and motivates for habit reversal.
  34. [34]
    A systematic review of evidence based treatments for lichen simplex ...
    We conducted a systematic review of the literature to evaluate treatments for LSC and provide an evidence-based summary of the current treatments as well as ...Missing: pharmacological | Show results with:pharmacological
  35. [35]
    Effectiveness of 0.1% mometasone furoate under hydrocolloid ...
    Mar 21, 2023 · This study proved the cost effectiveness of hydrocolloid dressing usage in patient with moderate to severe lichen simplex chronicus (LSC).
  36. [36]
    Topical tacrolimus for the treatment of lichen simplex chronicus
    We conclude that topical tacrolimus can be used as an effective, long‐lasting therapeutic modality in treating LSC, especially in sensitive skin areas such as ...
  37. [37]
    Lichen simplex - BAD Patient Hub - Skin Health Info
    Tacrolimus and pimecrolimus (topical calcineurin inhibitors) are licensed as creams / ointments to treat eczema and may reduce the skin inflammation and itch.
  38. [38]
    Treatment of prurigo nodularis and lichen simplex chronicus with ...
    Here five cases with lichen simplex chronicus and four cases with prurigo nodularis, who responded well to gabapentin, are presented.
  39. [39]
    Lichen Simplex Chronicus Treatment & Management
    Sep 6, 2024 · Treatment is aimed at reducing pruritus and minimizing existing lesions because rubbing and scratching cause lichen simplex chronicus.Approach Considerations · Medical Care
  40. [40]
    The antipruritic effect of 5% doxepin cream in patients with ... - PubMed
    Conclusion: Topical application of doxepin provides significant antipruritic activity with a favorable safety profile, suggesting a role for doxepin cream in ...
  41. [41]
    Lichen Simplex Chronicus Medication - Medscape Reference
    Sep 6, 2024 · Triamcinolone topical is for inflammatory dermatoses responsive to steroids; it decreases inflammation by suppressing the migration of ...
  42. [42]
    Case report: Abrocitinib: a potential therapeutic option for lichen ...
    Nov 13, 2024 · The observations of this case report indicate that abrocitinib could be a promising therapeutic agent for the treatment of LA in patients with ...
  43. [43]
    Topical Corticosteroids: Choice and Application - AAFP
    Mar 15, 2021 · Use topical corticosteroids to treat inflammatory skin diseases, including lichen sclerosus ... Lichen simplex chronicus. Melasma Nummular eczema
  44. [44]
    The efficacy and safety of targeted narrowband UVB therapy - NIH
    This study demonstrates that targeted narrowband UVB therapy is a safe and effective treatment alternative, particularly for alopecia areata, lichen simplex ...
  45. [45]
    Efficacy and Safety of Liquid Nitrogen Cryotherapy for Lichen ...
    A 2022 meta-analysis of clinical studies found that adding liquid nitrogen cryotherapy to conventional topical treatment significantly improved LSC outcomes ...
  46. [46]
    Fractional Carbon Dioxide Laser for Lichen Simplex Chronicus
    Aug 6, 2025 · Background: Lichen simplex chronicus (LSC) is a common itchy dermatosis. ... visual analog scale (VAS), and physician-reported outcomes in the ...Missing: itch | Show results with:itch
  47. [47]
    Evaluation of Botulinum Toxin Type A Injection in the Treatment of ...
    Dec 1, 2020 · CONCLUSION: Botulinum toxin A appears to be a safe and effective therapy for the improvement of localized recalcitrant itching in LSC, inverse ...Missing: 2020s | Show results with:2020s
  48. [48]
    Full article: Comparison of efficacy and safety of high-intensity ...
    The cure rate at six months after HIFU treatment was 60% and 65.8% in each group, similar to previous research. Li et al. treated 76 patients with squamous ...
  49. [49]
    Lichen Simplex Chronicus / Neurodermatitis - News-Medical
    Lichen simplex chronicus (LSC) is also known as neurodermatitis. This term refers to a chronic itchy condition of the skin that appears to get worse with ...
  50. [50]
    Sleep disturbance in patients with lichen simplex chronicus and its ...
    Nighttime pruritus is a common feature in LSC and may disrupt the sleep pattern. The aim of this study is to determine whether there are sleep abnormalities in ...Missing: chronic | Show results with:chronic